Nutriband Inc
Nutriband Inc is a medical equipment and supplies company that designs, develops, and markets wearable health monitoring devices, primarily focused on sleep apnea treatment and other respiratory conditions.
Business. Nutriband Inc (NTRB.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Nutriband is headquartered in the United States and is primarily listed on the NASDAQ stock exchange.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Nutriband Inc (NTRB.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Nutriband is headquartered in the United States and is primarily listed on the NASDAQ stock exchange.
Nutriband Inc operates with a capital structure that is highly liquid, as evidenced by $4.57 million in cash and equivalents, which significantly exceeds its total liabilities of $0.87 million. The company's liquidity position is further reinforced by a debt-to-equity ratio of 0.02, indicating minimal leverage. However, the company reported negative operating cash flow of $5.13 million, which raises concerns about its ability to sustain operations without external financing.
Profitability metrics are deeply negative, with a net loss of $8.23 million and an operating loss of $8.32 million. The return on equity is -1.23, which is far below the typical performance of companies in the medical equipment industry. The company's EV/EBITDA ratio is negative at -4.60, reflecting the unprofitable nature of its operations. These figures suggest that Nutriband is not currently generating returns that meet industry expectations.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is disclosed. Geographically, Nutriband's exposure is not explicitly detailed in the available data, but the company's operations are likely centered in the United States given the lack of international revenue disclosures. This lack of diversification increases the company's vulnerability to regional economic or regulatory shifts.
Nutriband's growth trajectory is uncertain, as the company reported a revenue of $2.04 million in the latest period. Analysts have assigned a mean price target of $15.00, which is significantly higher than the current market price of $3.51. However, the company's negative operating cash flow and net loss suggest that achieving this target will require substantial operational improvements or external capital infusions.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative operating cash flow and net loss raise concerns about the company's ability to maintain its current capital structure without issuing additional shares. The dilution potential is currently low, but the company's financial performance could necessitate equity financing in the near term.
Recent events include the publication of the latest financial data, which shows a significant decline in profitability. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational challenges. The lack of detailed disclosures limits the ability to assess the company's long-term viability.
- Nutriband Inc is a medical equipment company with a highly liquid balance sheet but significant operational losses.
- The company's negative operating cash flow and net loss indicate a need for external financing or operational improvements.
- Analysts have assigned a high price target, but the company's current financial performance does not support this optimism.
- The company's lack of segmental and geographic diversification increases its vulnerability to regional risks.
- Nutriband's risk profile is currently low, but its financial performance could necessitate equity financing in the near term.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Nutriband Inc Market data — financials · 2026-05-28
- Nutriband Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating income (YoY) (2026-01-31 vs 2025-01-31): 19.1%Derived (calculated)
- Net income (YoY) (2026-01-31 vs 2025-01-31): 21.5%Derived (calculated)
- Gross profit (YoY) (2026-01-31 vs 2025-01-31): -23.8%Derived (calculated)
- Capex (YoY) (2026-01-31 vs 2025-01-31): -94.2%Derived (calculated)
- EPS (diluted) (YoY) (2026-01-31 vs 2025-01-31): -160.6%Derived (calculated)
- Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -16.6%Derived (calculated)
- Total assets (YoY) (2026-01-31 vs 2025-01-31): 1.0%Derived (calculated)
- Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 3.9%Derived (calculated)
- Revenue (YoY) (2026-01-31 vs 2025-01-31): -4.8%Derived (calculated)
- R&D expense (YoY) (2026-01-31 vs 2025-01-31): -39.4%Derived (calculated)
- Cost of revenue (YoY) (2026-01-31 vs 2025-01-31): 5.3%Derived (calculated)
- EPS (basic) (YoY) (2026-01-31 vs 2025-01-31): -160.6%Derived (calculated)
- Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): 6.1%Derived (calculated)
- Net margin (FY 2026-01-31): -404.1%Derived (calculated)
- Gross margin (FY 2026-01-31): 27.8%Derived (calculated)
- Return on equity (FY 2026-01-31): -123.2%Derived (calculated)
- Return on assets (FY 2026-01-31): -109.0%Derived (calculated)
- Current ratio (FY 2026-01-31): 6.36xDerived (calculated)
- Debt-to-equity (FY 2026-01-31): 0.13xDerived (calculated)
- Operating cash flow (YoY) (2026-01-31 vs 2025-01-31): -11.0%Derived (calculated)
- Capex (annual): USD 5.32KSEC XBRL filing
- Operating income (annual): USD -8.32MSEC XBRL filing
- Revenue (annual): USD 2.04MSEC XBRL filing
- Cash & equivalents (annual): USD 4.57MSEC XBRL filing